Jiangsu NHWA Pharmaceutical Co., Ltd.

Initial public offerings in the US are in a slump, with just nine biopharmaceutical company IPOs during the first quarter, raising a total of $807m. The Q1 tally is a fraction of the offerings and the

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Seagen, RemeGen Partner Outside Asia, E

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Jan. 9-24. Deal Watc

Mergers & Acquisitions /In Vitro Diagnostics Clovis Oncology Inc. Roche Roche Diagnostics Roche Molecular Systems Inc. On the same day it received rights to a solid tumor compound from Pfizer Inc.